Milbemax vet. (1 - 2 kg)

1 x 4 pc

Film-coated tablet

Active substance

Praziquantel : 10 mg

Milbemycinoxim : 4 mg

ATC code

QP54AB51 Milbemycin oxime, comb.

QP54AB Milbemycins

QP54A Macrocyclic lactones

QP54 Endectocides

QP Antiparasitic products, insecticides and repellents

Species

Cats (≥ 0.5 - 2 kg).

Indications

For cats with, or at risk from mixed infections of cestodes, gastrointestinal nematodes, and/or heartworm. This veterinary medicinal product is only indicated when use against cestodes and nematodes or prevention of heartworm disease is indicated at the same time.

Cestodes

Treatment of tapeworm:

Dipylidium caninum,

Taenia spp.,

Echinococcus multilocularis.

Gastrointestinal nematodes

Treatment of:

Hookworm: Ancylostoma tubaeforme

Roundworm: Toxocara cati

Heartworm

Prevention of heartworm disease (Dirofilaria immitis) if concomitant treatment against cestodes is indicated.

Dose to be administered and administration route

Oral use.

Underdosing could result in ineffective use and may favour resistance development.

To ensure a correct dosage, body weight should be determined as accurately as possible.

Minimum recommended dose rate: 2 mg of milbemycin oxime and 5 mg of praziquantel per kg are given as a single dose. The veterinary medicinal product should be administered with or after some food. Doing so ensures optimum protection against heartworm disease.

Depending on the bodyweight of the cat, the practical dosing is as follows:

Weight	Tablets
0.5 – 1 kg	½ tablet
> 1 - 2 kg	1 tablet

The veterinary medicinal product can be inserted into a programme for prevention of heartworm disease if at the same time treatment against tapeworms is indicated. The duration of heartworm prevention is one month. For regular prevention of heartworm disease the use of a monosubstance is preferred.

Adverse reactions

Cats:

Very rare

(<1 animal / 10,000 animals treated, including isolated reports):

Digestive tract disorders (such as

Diarrhoea, Emesis)

Hypersensitivity reaction

Neurological disorders (such as Ataxia and Muscle tremor)

Systemic disorders (such as Lethargy)

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the package leaflet for contact details.